Loading...
Publication
Dislipidémias : a levedura do arroz vermelho como alternativa às estatinas
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 3.55 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Por todo o mundo, as doenças cardiovasculares são a principal causa de morte e incapacidade, sendo a dislipidémia um dos principais fatores de risco.
As guidelines internacionais recomendam como tratamento de primeira linha das dislipidémias os inibidores da coenzima 3-hidroxi-3-metilglutaril redutase (HMG-CoA), ou seja, as estatinas.
A manutenção da terapêutica é essencial para a prevenção da doença cardiovascular e diminuição de custos médicos e de hospitalização.
O grupo das estatinas está associado a efeitos adversos musculares bastante frequentes que muitas vezes conduzem ao abandono da terapêutica.
Recentemente, devido ao seu conteúdo em monacolina K e efeito no perfil lipídico, a suplementação oral com levedura do arroz vermelho (LAV) tem sido usada como uma alternativa no tratamento das dislipidemias.
Este trabalho tem como objetivo recolher a informação disponível sobre a LAV e avaliar o efeito da suplementação com LAV nas dislipidemias.
Diferentes ensaios clínicos demonstraram que a LAV é eficaz na redução do colesterol total, do colesterol-LDL e dos triglicéridos. Para além disso, os efeitos secundários são reduzidos e observam-se mais a nível gastrointestinal.
Apesar da LAV parecer ser segura e eficaz, são necessários mais estudos de longo termo e em sujeitos com doenças cardiovasculares, diabetes e outras patologias
para demonstrar a sua eficácia e segurança. Para além disso são necessários estudos
que levem em linha de conta a variedade de formulações e dosagens dos suplementos
de LAV disponíveis no mercado.
Throughout the world, cardiovascular diseases are the leading cause of death and disability, being that dyslipidemia is one of the main risk factors. The international guidelines recommend as first-line treatment for dyslipidemia the Coenzyme 3-Hydroxy-3-methylglutaryl reductase inhibitors (HMG-CoA), namely statins. Maintenance therapy is essential for the prevention of cardiovascular disease and reduced medical costs and hospitalization expenses. The group of the statins is associated with frequent muscle adverse side effects that often lead to the abandonment of therapeutics. Recently, due to its content in monacolin k and effect on the lipidic profile, oral supplementation with red yeast rice (RYR) has been used as an alternative in the treatment of dyslipidemia. This study aims to collect available information and evaluate the effect of RYR supplementation in dyslipidemia. Different clinical trials have shown that RYR is effective in reducing total cholesterol, LDL cholesterol and triglycerides. In addition, the side effects are reduced and mainly observed at a gastrointestinal level. However, despite the RYR appears to be safe and effective, more long-term studies and with subjects with cardiovascular disease, diabetes and other diseases are needed to demonstrate their efficacy and safety. In addition, studies are needed that take into account the variety of formulations and dosages of the supplements of RYR available on the market.
Throughout the world, cardiovascular diseases are the leading cause of death and disability, being that dyslipidemia is one of the main risk factors. The international guidelines recommend as first-line treatment for dyslipidemia the Coenzyme 3-Hydroxy-3-methylglutaryl reductase inhibitors (HMG-CoA), namely statins. Maintenance therapy is essential for the prevention of cardiovascular disease and reduced medical costs and hospitalization expenses. The group of the statins is associated with frequent muscle adverse side effects that often lead to the abandonment of therapeutics. Recently, due to its content in monacolin k and effect on the lipidic profile, oral supplementation with red yeast rice (RYR) has been used as an alternative in the treatment of dyslipidemia. This study aims to collect available information and evaluate the effect of RYR supplementation in dyslipidemia. Different clinical trials have shown that RYR is effective in reducing total cholesterol, LDL cholesterol and triglycerides. In addition, the side effects are reduced and mainly observed at a gastrointestinal level. However, despite the RYR appears to be safe and effective, more long-term studies and with subjects with cardiovascular disease, diabetes and other diseases are needed to demonstrate their efficacy and safety. In addition, studies are needed that take into account the variety of formulations and dosages of the supplements of RYR available on the market.
Description
Dissertação para obtenção do grau de Mestre no Instituto Universitário Egas Moniz
Keywords
Levedura do arroz vermelho Estatinas Dislipidémia Monacolina K Doenças cardiovasculares